10、Yu Y, Guo Q, Zhang Y, et al. Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-
[2] Yu, Y. et al. Efficacy and safety outcomes of Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study): Long-term follow-up analysis[J]. Annals of Oncology,...
2.Y. Wu, J. Zhao, J. Hu,etc.388P - Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study[J].ESMO Asia Congress 2022.3. 牛娜.非小细胞肺癌 ＭＥＴ基因...
First case report of Tepotinib in a pt with Lung adenoca with MET exon 14 skipping mutation. Good partial response on ct at 6 weeks. No grade 2 or 3 toxicities. subjective benefit continues.doi:10.13140/RG.2.2.16999.78241Bulusu Venkata...
EXON 14 SKIPPING MUTATION 首页/癌基因/MET/ EXON 14 SKIPPING MUTATION MET基因编码的蛋白为肝细胞生长因子受体HGFR,具有酪氨酸激酶活性,与多种癌基因产物和调节蛋白相关,参与细胞信息传导、细胞骨架重排的调控,是细胞增殖、分化和运动的重要因素。目前认为,c-met与多种癌的发生和转移密切相关,研究表明,许多肿瘤病人...
1C). There was no other gene mutation (Fig. 1B, lower row). The structures of wild-type and novel MET exon 14 skipping were analyzed by SWISSMODEL and are shown in Figures 1D and 1E, respectively. After frameshift of c.3019_3028+29delinsACCTA (p.Phe1007fs), the core binding ...
2023年10月，Drug Target Insights杂志发表了一篇题为《Optimal treatment for metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation》的文章，这篇病例报告详细介绍了一位罹患携带METex14突变的转移性NSCLC，并检测出高PD-L1表达（肿瘤比例得分≥50%）的86岁老年男性患者。该患者接受了...
Xu Z . MET Exon 14 Skipping Alterations in Non-small Cell Lung Carcinoma—Current Understanding and Therapeutic Advances[J]. Oncology & Hematology Review (US), 2021, 16(2):100.[6] Fujino T , Suda K , Mitsudomi T . Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Curren...
MET Exon 14 Skipping Mutation inNon-Small Cell Lung Cancer Identifiedby Anchored Multiplex PCR and Next-Generation SequencingTafe LJde Abreu FBPeterson JDTsongalis GJ
3. Choi W, Park SY, Lee Y, et al. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification. Cancer Res Treat 2021;53:1024-32. 4. Mathieu LN, Larkins E, Akinboro O, et al. FDA Approval Summar...